US10206877 — Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2035-04-14 · 9y remaining
What this patent protects
This patent protects pharmaceutical compositions that combine multiple therapeutic agents for treating cystic fibrosis transmembrane conductance regulator mediated diseases.
USPTO Abstract
The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3026 |
— | Kalydeco |
U-3027 |
— | Kalydeco |
U-4092 |
— |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.